Endometrial carcinogenesis and its relation to oestrogens.
The epidemiological evidence suggesting an association between the administration of exogenous oestrogens and an increased risk of developing endometrial adenocarcinoma is critically reviewed and it is concluded that the case for oestrogens being a cause of endometrial cancer is proven. The benefits flowing from preventing postmenopausal osteoporosis by oestrogen replacement therapy are assessed and contrasted with the danger to life posed by endometrial adenocarcinoma: it is pointed out that the type of neoplasm developing in patients taking oestrogens is well differentiated, nonaggressive and easily cured, the survival rate being very high. The addition of progestational agents to the therapeutic regime may prevent the development of endometrial carcinoma but could introduce a risk of cardiovascular disease.
D000230:Adenocarcinoma / Q000209:etiology*; D045166:Estradiol Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause; D012106:Research; D012306:Risk; D014594:Uterine Neoplasms / Q000209:etiology*
D045166:Estradiol Congeners